Efficacy and safety of low dose oral isotretinoin in comparison with oral itraconazole in the treatment of seborrheic dermatitis among patients attending Erbil dermatology teaching center in Erbil City
Background and objective: Seborrheic dermatitis is chronic skin disease with exacerbation and remission, many topical and systemic therapies were used, including oral antifungal itraconazole, oral isotretinoin efficacy in the treatment of seborrheic dermatitis less studied. This study aimed to compare the efficacy and safety of low dose oral isotretinoin and oral itraconazole in the treatment of patients with seborrheic dermatitis.
Methods: A total of 68 patients with seborrheic dermatitis were participating in a randomized, parallel-group study. One group (n = 31) took 200-mg/day oral itraconazole for one week of the first month, followed by 200 mg for the first two days of the next two months. The second group (n = 37) took oral isotretinoin 20 mg twice weekly for three months. Seborrheic dermatitis area severity index and intensity of itching and burning sensation were calculated before, during three months and one month after treatment.
Results: Both drugs significantly reduced the severity of seborrheic dermatitis (P <0.05). When the two groups were compared, patients taking oral isotretinoin showed a significantly greater decrease in seborrheic dermatitis area severity index score than itraconazole group particularly in the second and third months of treatment.
Conclusion: Low dose oral isotretinoin is more effective than oral itraconazole in treating seborrhea dermatitis.
Berth-JonesJ. “Seborrheic dermatitis,” in Tony Burns. Rook’s Text Book of Dermatology. 7thed. London: Blackwell; 2010. P. 29–31.
Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol 2014; 28:16–26.
Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Therapy Lett 2010; 15:1–4.
Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13-26.
Palamaras I, Kyriakis KP, Stavrianeas NG. Seborrheic dermatitis: lifetime detection rates. J Eur Acad Dermatol Venereol 2012; 26:524–6.
Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC. Seborrheicdermatitis. An Bras Dermatol 2011; 86(6):1061–71.
Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004; 208:89–93.
Baysal V, Yildirim M, Ozcanli C, Ceyhan AM. Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol 2004; 43(1):63–6.
Comert A, Bekiroglu N, Gurbuz O, Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol 2007; 8:235–8.
De souzaleao Kamamoto, Sanudo A, Hassun KM, Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol 2017; 56:80-5.
Peyri J, Lleonart M, Grupoespañol del Studio SEBDERM Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr 2007; 98(7):476–82.
Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trail. Am J Clin Dermatol 2015; 16:431-7.
Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol 2005; 19:172–5.
Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhea and acne. Dermatology 1998; 196:140–7.
Geissler SE, Michelsen S, Plewig G. Very low-dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 2003; 1:952–8.
Zoubolis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006; 126:2154–6.
Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387–96.
Sehgal VN, Khandpur S. Antifungal agents: unapproved uses, dosages, or indications. Clin Dermatol 2002; 20:481–9.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).